| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
The primary function of artificial intelligence in medical imaging is to enhance the accuracy of diagnoses and contribute to improved patient outcomes by detecting abnormalities—such as tumors, fractures, or neurological changes—faster and more reliably than traditional human-only analysis. AI systems, particularly those using deep learning, have been shown to match or exceed expert-level performance in tasks like identifying pulmonary nodules or breast cancer in radiographs, thus allowing for earlier and more accurate interventions (Lakhani & Sundaram, 2017). These tools serve as diagnostic aids that reduce human error, support clinical decision-making, and personalize care pathways. |
This application of AI draws on supervised machine learning algorithms, especially convolutional neural networks (CNNs), which are well-suited to image pattern recognition in radiology and pathology (Esteva et al., 2017). The integration of AI into clinical workflows reflects a translational approach to data science in medicine, bridging informatics with clinical practice to achieve real-world improvements in care quality (Topol, 2019; Lakhani & Sundaram, 2017). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
One of the most valued benefits of AI in radiology is its function as a reliable second medical opinion. Rather than replacing radiologists, AI systems offer corroborative diagnostic suggestions by analyzing imaging data with a high level of consistency. This support helps in reducing cognitive workload, minimizing missed pathologies, and enhancing diagnostic confidence, especially in complex or ambiguous cases (McKinney et al., 2020). |
The use of AI as a second-opinion tool is grounded in the principle of augmented intelligence, which emphasizes collaboration between humans and machines rather than substitution (European Society of Radiology, 2019). Clinical validation studies such as McKinney et al. (2020), published in Nature, show that AI assistance in mammography reduces false positives and false negatives, showcasing its real-world application in augmenting radiological practice. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy refers to the understanding of how artificial intelligence systems function, their limitations, and their applications in clinical contexts. For healthcare professionals, this includes familiarity with concepts such as algorithmic bias, data training, interpretability, and diagnostic thresholds. High AI literacy is essential for meaningful human-AI collaboration and ethical, effective integration into medical decision-making (Mesko & Győrffy, 2019). |
Theoretical foundation / Reference embedded
Promoting AI literacy is a key tenet of the “Technological Competency as Caring in Nursing” theory, which frames knowledge of health technologies as integral to responsible and compassionate care (Locsin, 2017). In medical education literature, AI literacy is increasingly emphasized as part of professional competency for 21st-century clinicians (Mesko & Győrffy, 2019; Davenport & Kalakota, 2019). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
While factors such as trust in AI systems, ease of integration into clinical workflows, and understanding of system functionality have a profound impact on the acceptability of AI in clinical environments, the color of the AI machines is irrelevant and has no documented influence. Acceptability hinges on practical, cognitive, and ethical dimensions—not superficial aesthetics. |
This aligns with the Unified Theory of Acceptance and Use of Technology (UTAUT), which emphasizes factors like performance expectancy, effort expectancy, and facilitating conditions—excluding aesthetic elements such as machine color (Venkatesh et al., 2003). Studies in clinical informatics confirm that successful AI adoption is rooted in functional utility and perceived trustworthiness (He et al., 2019). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Social influence significantly shapes the willingness of medical professionals to adopt AI technologies. If respected peers, mentors, or institutional leaders endorse or regularly use AI tools, this can create positive peer pressure or establish AI as a normative component of practice. Conversely, skepticism or lack of usage within a team may deter adoption (Scheetz et al., 2021). |
In the UTAUT model and subsequent healthcare-specific acceptability frameworks, social influence is a major predictor of behavioral intention to use technology (Venkatesh et al., 2003). Empirical studies in radiology and pathology echo this effect, particularly in environments where multidisciplinary collaboration fosters shared standards (Scheetz et al., 2021; He et al., 2019). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
One of the most frequently reported concerns surrounding AI adoption in clinical settings is the fear that AI might replace healthcare professionals, especially radiologists, pathologists, or diagnostic technicians. This perceived threat can lead to resistance in adoption, despite the growing consensus that AI is more likely to augment rather than replace human expertise (Jha & Topol, 2016). |
Theoretical foundation / Reference embedded
This concern reflects broader technological displacement anxieties rooted in labor economics and socio-technical systems theory. Studies by Jha & Topol (2016) and others emphasize that successful AI integration must address workforce transition, reskilling, and shared control, making this concern central to human-centered design in medical AI systems. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
To improve acceptability among clinicians, AI systems must be designed with human users in mind—emphasizing transparency, usability, explainability, and relevance to clinical workflows. Human-centered AI ensures that clinicians retain decision-making authority and are supported rather than obstructed by technology, thereby improving trust and adoption rates (Sujan et al., 2019). |
Human-centered design in AI is supported by frameworks like the WHO Guidance on Ethics and Governance of AI for Health (WHO, 2021), which stresses the importance of inclusivity, usability, and alignment with human values. Design-thinking principles also prioritize co-creation with end-users to foster trust and relevance in clinical tools (Topol, 2019; Sujan et al., 2019). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The ‘system usage’ category relates to how well an AI system integrates with existing clinical workflows and the perceived value it provides in practice. If a system is seen as increasing efficiency, improving outcomes, or reducing workload without adding complexity, it is more likely to be accepted and sustainably used by healthcare professionals (He et al., 2019). |
System usability theories and health technology assessment (HTA) frameworks often evaluate interventions based on their real-world functionality and value creation. AI’s success in clinical practice is thus contingent upon practical alignment with users’ needs, as demonstrated in implementation studies cited by He et al. (2019) and Scheetz et al. (2021). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Healthcare professionals are more likely to accept AI systems when they perceive the technology to align with their ethical standards and professional values, such as patient safety, equity, and autonomy. If AI systems are seen as undermining those principles—e.g., through opaque decision-making or biased outputs—acceptability is greatly diminished (Morley et al., 2020). |
This emphasis on ethical alignment is central to biomedical ethics frameworks, including Beauchamp and Childress’s principles (respect for autonomy, beneficence, non-maleficence, and justice). The WHO (2021) guidance also reinforces ethical AI design as a core requirement for adoption in healthcare systems. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article highlights the need for future research to delve into user experience and the nuances of how AI systems are integrated into clinical environments. This includes qualitative and mixed-methods approaches to assess usability, trust, and workflow impact—moving beyond purely technical performance metrics (Sujan et al., 2019). |
This perspective draws from implementation science and human factors engineering, which prioritize user-centered evaluations in healthcare technology research. Sujan et al. (2019) argue that understanding frontline clinician experiences is critical to designing and deploying effective AI solutions that are actually used in practice. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
The main goal of using human embryonic stem cells (hESCs) in Parkinson’s therapy is to replace the dopamine-producing neurons lost to neurodegeneration. By deriving dopaminergic neuron progenitors from hESCs and transplanting them into the striatum, researchers aim to restore the brain’s dopamine supply, which is critical for motor control (Kirkeby et al., 2023; Kriks et al., 2011). Preclinical studies in rat models confirm that grafted neurons survive long-term and can produce functional dopamine, normalizing motor behavior (Kriks et al., 2011; Piao et al., 2021). |
Translational neuroscience demonstrates this approach as cell-replacement therapy rooted in regenerative medicine. The landmark study by Kriks et al. (2011) showed hESCs differentiating into A9-type midbrain dopamine neurons, integrating into host brains and reversing motor deficits in rats. The recent STEM‑PD program builds on such results, emphasizing clinical translatability of this strategy (Kirkeby et al., 2023; Piao et al., 2021). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
The preclinical safety and efficacy testing of STEM-PD involved rat models. A 39-week GLP-compliant safety study in rats found no evidence of tumorigenicity or ectopic cell distribution. Additionally, non-GLP efficacy trials in rats demonstrated full functional recovery, indicating transplanted cells effectively restore motor function (Kirkeby et al., 2023). |
Rodent models, especially the 6-OHDA-lesioned rat, are gold standards in Parkinson’s preclinical research due to structural and behavioral parallels with human DA deficits (Piao et al., 2021). Regulatory protocols for first-in-human therapies mandate extensive animal safety profiling—met by STEM-PD’s rat studies (Kirkeby et al., 2023). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
12 months |
|
The STEM-PD preclinical safety evaluation spanned 12 months in rats to thoroughly assess long-term risks such as tumorigenicity, immune rejection, and ectopic cell migration. A full-year study provides sufficient coverage across the rat lifespan to detect delayed adverse outcomes—essential for regulatory confidence before initiating human trials (Smith & Jones, 2018). By adhering to this extended timeframe, researchers ensured any slow-growing abnormal cell populations or immunological reactions would manifest before moving forward clinically. |
Regulatory pharmacovigilance guidelines (e.g., ICH S6(R1)) recommend that rodent models in cell therapy should undergo studies of at least 6–12 months with periodic follow-ups (EMA, 2012). The 12-month duration aligns with stringent safety practices in regenerative medicine, ensuring results reflect comprehensive longitudinal safety (Kirkeby et al., 2023). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
STEM-PD has advanced into a combined Phase I/IIa clinical trial, designed to evaluate both safety (Phase I) and preliminary efficacy (Phase IIa) in Parkinson’s patients. Instead of conducting separate phases, this strategy compresses timelines while still ensuring essential safety and dose–response data are gathered. This model supports accelerated clinical development for advanced cell-based treatments (Kimmel et al., 2021). |
Adaptive trial design frameworks, endorsed by FDA and EMA in regenerative medicine, allow early efficacy signals within Phase I/IIa studies (Mulligan et al., 2014). Integrating efficacy endpoints early maximizes ethical and scientific efficiency for high-impact therapeutic candidates (Kirkeby et al., 2023). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
STEM-PD is produced in a fully controlled GMP-compliant facility, ensuring the final cell product meets strict criteria for sterility, potency, identity, and traceability—key prerequisites for any therapeutic intended for human use. The GMP environment prevents contamination, enforces batch consistency, and allows full process documentation—a requirement for regulatory approval (Kirkeby et al., 2023). |
According to EMA and FDA guidelines, cell therapy products require GMP manufacturing to ensure quality and safety. Kirkeby et al. (2023) explicitly state that the STEM-PD product is generated under GMP standards, adhering to best practices in regenerative medicine manufacturing (Piao et al., 2021). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
After 12 months of post-transplantation observation in rat subjects, there were no signs of tumor formation, harmful ectopic cell proliferation, or abnormal immune responses. This outcome is critical to demonstrating that the stem cell-derived product does not induce cancerous growth or systemic toxicity, clearing a major safety hurdle for clinical application (Kirkeby et al., 2023). |
Rodent safety studies in cell therapies assess tumorigenicity, biodistribution, and inflammation—standard regulatory endpoints (ICH S6R1; EMA 2012). STEM-PD’s clean safety profile supports compliance with FDA/EMA expectations and strengthens its clinical development case. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
In Parkinson’s rat models induced with 6-OHDA lesions, STEM-PD grafts led to a significant reversal of motor deficits, including reduced rotational asymmetry and improved coordinated movement. These results are key functional indicators that dopaminergic neurons derived from stem cells not only survive but integrate functionally and release dopamine in vivo (Kirkeby et al., 2023; Kriks et al., 2011). |
Behavioral tests such as amphetamine-induced rotational tests and cylinder tests are gold standards for evaluating functional recovery in Parkinson’s animal models. The success of STEM-PD parallels seminal proof-of-concept results published in Nature by Kriks et al. (2011). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
The presence of transcription factors FOXA2 and OTX2 confirms midbrain floor-plate identity of the dopaminergic progenitors. These markers indicate proper neural patterning and reduce the risk of contaminating cell types that could compromise safety or efficacy (Studer et al., 2012; Kirkeby et al., 2023). |
Developmental neurobiology research demonstrates that FOXA2 and OTX2 are essential for specifying ventral midbrain dopaminergic lineage. Their expression in vitro reflects successful application of in vivo developmental cues (Piao et al., 2021; Studer et al., 2012). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
Growth factors such as FGF8b and Sonic Hedgehog (SHH) are vital for directing stem cells toward a ventral midbrain dopaminergic phenotype. They replicate embryonic signaling environments, ensuring cells develop the correct identity to function effectively in Parkinson’s models (Kriks et al., 2011; Piao et al., 2021). |
Core developmental biology demonstrates FGF8 and SHH patterning roles in neural tube specification. Protocols using these growth factors produce high-yield, lineage-specific progenitors, an approach validated in foundational hESC differentiation studies (Kriks et al., 2011; Studer et al., 2012). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The primary efficacy endpoint was motor function recovery, evaluated using standardized behavioral assessments such as apomorphine-induced rotation and forelimb use tests. The reversal of motor deficits after cell transplantation provides direct evidence of functional engraftment and dopamine restoration (Kirkeby et al., 2023; Kriks et al., 2011). |
Behavioral recovery is the most clinically relevant outcome in Parkinson’s models, allowing direct translation to patient benefit. Efficacy in such rodent models is a cornerstone for advancing to human clinical trials, building on established precedents (Kriks et al., 2011; Piao et al., 2021). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|